In Oklahoma, Compound Laws tracks 19 compounds: 6 legal to sell at retail, 5 restricted, 1 in a gray area, 1 illegal, 1 not yet verified, and 5 whose status varies by product form. Verified through October 22, 2026.
96f183eb66e96c36[OK AG 2026 Hemp Clarification Letter:] "Total THC is measured as THC plus 87.7 percent of THCA" [...] [Current law:] "hemp products are restricted to test no more than 0.3% Total THC." [Starting Nov. 12, 2026, intermediate products no more than 0.3% total THC post-decarboxylation and final marketplace products no more than 0.4 mg total THC per container.] [Statute text not fetched; letter summarized.]
13e4b92e24135859§2-3-411. Cannabidiol sourcing. Cannabidiol shall not be processed in the State of Oklahoma from any sources which would be in violation of the United States Code or the Code of Federal Regulations. Added by Laws 2019, c. 91, § 11, emerg. eff. April 18, 2019. §2-3-601. Short title - Oklahoma Industrial Hemp Remediation Program - Definitions. A. This act shall be known and may be cited as the "Oklahoma Industrial Hemp Remediation Program". B. As used in the Oklahoma Industrial Hemp Remediation Program, the following words and terms, and any derivative of such words or terms, shall have the following meanings, unless the context clearly indicates otherwise: 1. "Cannabis" means a genus of flowering plants in the family Cannabaceae of which Cannabis sativa is a species and Cannabis indica and Cannabis ruderalis are subspecies thereof. Cannabis refers to any form of the plant in which the delta-9 tetrahydrocannabinol concentration on a dry-weight basis has not yet been determined; 2. "Certified laboratory" means the laboratory operated by the Oklahoma Department of Agriculture, Food, and Forestry or a laboratory located in Oklahoma that is certified by the Department; 3. "Commercial sale" means the sale of a product in the stream of commerce at retail, at wholesale or on the Internet; 4. "CSA" means the federal Controlled Substances Act; 5. "DEA" means the United States Drug Enforcement Administration; 6. "Department" means the Oklahoma Department of Agriculture, Food, and Forestry; 7. "Hemp" means the plant Cannabis sativa L. and any part of such plant including, but not limited to, the seeds and all derivatives, extracts, cannabinoids, isomers, acids, salts and salts of isomers, whether growing or not, and grown from a certified seed with a delta-9 tetrahydrocannabinol concentration of not more than three-tenths of one percent (0.3%) on a dry-weight basis. Hemp and hemp-derived cannabinoids, including cannabidiol, shall be considered an agricultural commodity and not a controlled substance due to the presence of hemp or hemp-derived cannabinoids; 8. "Hemp Program" means the Oklahoma Industrial Hemp Remediation Program and any final ruling from the USDA; 9. "Law enforcement" means any federal, state or local agencies responsible for maintaining public order and enforcing the law; 10. "License" means the written authorization by the Department for any person to grow, process, handle or transport certified seeds or hemp in this state; 11. "Person" means any natural person or any corporation, general partnership, limited partnership, limited liability partnership, limited liability company, trust, estate, charitable organization, joint stock company, joint venture, association or any other business or similar organization recognized by the state; 12. "Processor" means any person who is licensed by the Department to process hemp in this state; 13. "State" means the State of Oklahoma; 14. "THC" means delta-9 tetrahydrocannabinol, which is a psychoactive component in cannabis plants; 15. "Tracking software" means software that is approved by the Department and is capable of transparently tracking hemp in any state or form whatsoever including, but not limited to, a certified seed, any stage of growth, processing or handling, and any hemp product; and 16. "USDA" means the United States Department of Agriculture. C. In the event that any hemp produced under the Hemp Program is determined by testing results to be noncompliant with the Hemp Program, the person holding the license for the noncompliant hemp may request approval from the Department to remediate the noncompliant hemp. D. If the Department approves the remediation of the noncompliant hemp, the person holding the license shall promptly have the noncompliant hemp extracted by a licensed processor into concentrated form and the hemp concentrate shall be sampled by a certified laboratory for compliance with USDA levels for THC in concentrated form. E. If the samples of the hemp concentrate are below USDA levels for THC, the hemp concentrate shall be compliant as a hemp product with the Hemp Program and may be used in commercial sales. F. If the samples of the hemp concentrate are above the USDA levels for THC, the hemp concentrate shall be noncompliant with the Hemp Program and shall be destroyed in accordance with the CSA and DEA regulations found at 21 C.F.R., Section 1317.15, as enforced by federal, state and local law enforcement. The person holding the license for the noncompliant hemp concentrate shall promptly notify the Department and USDA of its intent to destroy the noncompliant hemp concentrate and verify destruction by submitting required documentation using the tracking software. Added by Laws 2021, c. 159, § 1, eff. Nov. 1, 2021.
55d4c8c07c14f1f7B. As used in the Oklahoma Industrial Hemp Remediation Program, the following words and terms, and any derivative of such words or terms, shall have the following meanings, unless the context clearly indicates otherwise: 7. "Hemp" means the plant Cannabis sativa L. and any part of such plant including, but not limited to, the seeds and all derivatives, extracts, cannabinoids, isomers, acids, salts and salts of isomers, whether growing or not, and grown from a certified seed with a delta-9 tetrahydrocannabinol concentration of not more than three-tenths of one percent (0.3%) on a dry-weight basis. Hemp and hemp-derived cannabinoids, including cannabidiol, shall be considered an agricultural commodity and not a controlled substance due to the presence of hemp or hemp-derived cannabinoids; 14. "THC" means delta-9 tetrahydrocannabinol, which is a psychoactive component in cannabis plants;
a353076997f77039**63 O.S. § 2-204(C) (the trap — names the neighbors, not 4-HO-MET)** — "Any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers … 55. 4-hydroxy-N, N-diethyltryptamine; 56. 4-hydroxy-N, N-diisopropyltryptamine; 57. 5-methoxy-N, N-diisopropyltryptamine; 58. 4-hydroxy-N-isopropyl-N-methyltryptamine;"
— 63 O.S. § 2-204(C), 2025 version (amended through Laws 2024, c. 308), https://law.justia.com/codes/oklahoma/2025/title-63/section-63-2-204/ (MIRROR: Justia). 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET) appears **nowhere** in the section.
**63 O.S. § 2-101(48) ("Synthetic controlled substance")** — "'Synthetic controlled substance' means a substance: (1) the chemical structure of which is substantially similar to the chemical structure of a controlled dangerous substance in Schedule I or II, (2) which has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled dangerous substance in Schedule I or II, or (3) with respect to a particular person, which such person represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than [that] of a controlled dangerous substance in Schedule I or II. … c. Synthetic controlled substance does not include: (1) a controlled dangerous substance, (2) any substance for which there is an approved new drug application, … or (4) any substance to the extent not intended for human consumption …"
— 63 O.S. § 2-101(48), https://law.justia.com/codes/oklahoma/title-63/section-63-2-101/ (MIRROR: Justia, 2025).1cf3a1fb010cfd19§63-2-204. Schedule I. The controlled substances listed in this section are included in Schedule I and include any material, compound, mixture or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically excepted, when the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation. A. Any of the following opiates including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, when the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation: 1. Acetylmethadol; 2. Allylprodine; 3. Alphacetylmethadol; 4. Alphameprodine; 5. Alphamethadol; 6. Benzethidine; 7. Betacetylmethadol; 8. Betameprodine; 9. Betamethadol; 10. Betaprodine; 11. Clonitazene; 12. Dextromoramide; 13. Dextrorphan (except its methyl ether); 14. Diampromide; 15. Diethylthiambutene; 16. Dimenoxadol; 17. Dimepheptanol; 18. Dimethylthiambutene; 19. Dioxaphetyl butyrate; 20. Dipipanone; 21. Ethylmethylthiambutene; 22. Etonitazene; 23. Etoxeridine; 24. Furethidine; 25. Hydroxypethidine; 26. Isotonitazene; 27. Ketobemidone; 28. Levomoramide; 29. Levophenacylmorphan; 30. Metonitazene; 31. Morpheridine; 32. N-desethyl isotonitazene; 33. N-pyrrolidino protonitazene; 34. Noracymethadol; 35. Norlevorphanol; 36. Normethadone; 37. Norpipanone; 38. Phenadoxone; 39. Phenampromide; 40. Phenomorphan; 41. Phenoperidine; 42. Piritramide; 43. Proheptazine; 44. Properidine; 45. Protonitazene; 46. Racemoramide; or 47. Trimeperidine. B. Any of the following opium derivatives, their salts, isomers, and salts of isomers, unless specifically excepted, when the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: 1. Acetorphine; 2. Acetyldihydrocodeine; 3. Benzylmorphine; 4. Codeine methylbromide; 5. Codeine-N-Oxide; 6. Cyprenorphine; 7. Desomorphine; 8. Dihydromorphine; 9. Etorphine; 10. Heroin; 11. Hydromorphinol; 12. Methyldesorphine; 13. Methylhydromorphine; 14. Morphine methylbromide; 15. Morphine methylsulfonate; 16. Morphine-N-Oxide; 17. Myrophine; 18. Nicocodeine; 19. Nicomorphine; 20. Normorphine; 21. Phoclodine; 22. Thebacon; 23. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide (Acetyl fentanyl); 24. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide (Crotonyl fentanyl); 25. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2- furancarboxamide (Furanyl fentanyl); 26. N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP); 27. N-(1-phenethylpiperidin-4-yl)-N- phenylcyclopropanecarboxamide (Cyclopropyl fentanyl); or 28. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide (Butyrl fentanyl). C. Any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, unless specifically excepted, when the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: 1. Methcathinone; 2. 3, 4-methylenedioxy amphetamine; 3. 3, 4-methylenedioxy methamphetamine; 4. 5-methoxy-3, 4-methylenedioxy amphetamine; 5. 3, 4, 5-trimethoxy amphetamine; 6. Bufotenine; 7. Diethyltryptamine; 8. Dimethyltryptamine; 9. 4-methyl-2, 5-dimethoxyamphetamine; 10. Ibogaine; 11. Lysergic acid diethylamide; 12. Marijuana; 13. Mescaline; 14. N-benzylpiperazine; 15. N-ethyl-3-piperidyl benzilate; 16. N-methyl-3-piperidyl benzilate; 17. Psilocybin; 18. Psilocyn; 19. 2, 5 dimethoxyamphetamine; 20. 4 Bromo-2, 5-dimethoxyamphetamine; 21. 4 methoxyamphetamine; 22. Cyclohexamine; 23. Salvia Divinorum; 24. Salvinorin A; 25. Thiophene Analog of Phencyclidine. Also known as: 1-(1-(2- thienyl) cyclohexyl) piperidine; 2-Thienyl Analog of Phencyclidine; TPCP, TCP; 26. Phencyclidine (PCP); 27. Pyrrolidine Analog for Phencyclidine. Also known as 1-(1- Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP; 28. 1-(3-trifluoromethylphenyl) piperazine; 29. Flunitrazepam; 30. B-hydroxy-amphetamine; 31. B-ketoamphetamine; 32. 2,5-dimethoxy-4-nitroamphetamine; 33. 2,5-dimethoxy-4-bromophenethylamine; 34. 2,5-dimethoxy-4-chlorophenethylamine; 35. 2,5-dimethoxy-4-iodoamphetamine; 36. 2,5-dimethoxy-4-iodophenethylamine; 37. 2,5-dimethoxy-4-methylphenethylamine; 38. 2,5-dimethoxy-4-ethylphenethylamine; 39. 2,5-dimethoxy-4-fluorophenethylamine; 40. 2,5-dimethoxy-4-nitrophenethylamine; 41. 2,5-dimethoxy-4-ethylthio-phenethylamine; 42. 2,5-dimethoxy-4-isopropylthio-phenethylamine; 43. 2,5-dimethoxy-4-propylthio-phenethylamine; 44. 2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine; 45. 2,5-dimethoxy-4-tert-butylthio-phenethylamine; 46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine; 47. 5-methoxy-N, N-dimethyltryptamine; 48. N-methyltryptamine; 49. A-ethyltryptamine; 50. A-methyltryptamine; 51. N, N-diethyltryptamine; 52. N, N-diisopropyltryptamine; 53. N, N-dipropyltryptamine; 54. 5-methoxy-a-methyltryptamine; 55. 4-hydroxy-N, N-diethyltryptamine; 56. 4-hydroxy-N, N-diisopropyltryptamine; 57. 5-methoxy-N, N-diisopropyltryptamine; 58. 4-hydroxy-N-isopropyl-N-methyltryptamine; 59. 3,4-Methylenedioxymethcathinone (Methylone); 60. 3,4-Methylenedioxypyrovalerone (MDPV); 61. 3-Methylmethcathinone (Metaphedrone); 62. 4-Methylmethcathinone (Mephedrone); 63. 4-methoxymethcathinone; 64. 4-Fluoromethcathinone; 65. 3-Fluoromethcathinone; 66. 1-(8-bromobenzo 1,2-b;4,5-b’ difuran-4-yl)-2-aminopropane; 67. 2,5-Dimethoxy-4-chloroamphetamine; 68. 4-Methylethcathinone; 69. Pyrovalerone; 70. N,N-diallyl-5-methoxytryptamine; 71. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone); 72. B-keto-N-Methylbenzodioxolylbutanamine (Butylone); 73. B-keto-Methylbenzodioxolylpentanamine (Pentylone); 74. Alpha-Pyrrolidinopentiophenone; 75. 4-Fluoroamphetamine; 76. Pentedrone; 77. 4’-Methyl-a-pyrrolidinohexaphenone; 78. 2,5-dimethoxy-4-(n)-propylphenethylamine; 79. 2,5-dimethoxyphenethylamine; 80. 1,4-Dibenzylpiperazine; 81. N,N-Dimethylamphetamine; 82. 4-Fluoromethamphetamine; 83. 4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25C-NBOMe); 84. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe); 85. 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine (25B-NBOMe); 86. 1-(4-Fluorophenyl)piperazine; 87. Methoxetamine; 88. 3,4-dichloro-N[2-dimethylamino)cyclohexyl]-N- methylbenzamide; 89. N-ethyl hexadrone; 90. Isopropyl-U-47700; 91. Para-fluorobutyrl fentanyl; 92. Para-fluorofentanyl (pFF); 93. Fluoro isobutryrl fentanyl; 94. 3-Hydroxy Phencyclidine (PCP); 95. 3-methoxy Phencyclidine (PCP); 96. Flualprazolam; or 97. Flubromazolam. D. Unless specifically excepted or unless listed in a different schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having stimulant or depressant effect on the central nervous system: 1. Fenethylline; 2. Mecloqualone; 3. N-ethylamphetamine; 4. Methaqualone; 5. Gamma-Hydroxybutyric Acid, also known as GHB, gamma- hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium oxybate, and sodium oxybutyrate; 6. Gamma-Butyrolactone (GBL) as packaged, marketed, manufactured or promoted for human consumption, with the exception of legitimate food additive and manufacturing purposes; 7. Gamma Hydroxyvalerate (GHV) as packaged, marketed, or manufactured for human consumption, with the exception of legitimate food additive and manufacturing purposes; 8. Gamma Valerolactone (GVL) as packaged, marketed, or manufactured for human consumption, with the exception of legitimate food additive and manufacturing purposes; 9. 1,4 Butanediol (1,4 BD or BDO) as packaged, marketed, manufactured, or promoted for human consumption with the exception of legitimate manufacturing purposes; or 10. N-ethylpentylone. E. 1. The following industrial uses of Gamma-Butyrolactone, Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol are excluded from all schedules of controlled substances under this title: a. pesticides, b. photochemical etching, c. electrolytes of small batteries or capacitors, d. viscosity modifiers in polyurethane, e. surface etching of metal coated plastics, f. organic paint disbursements for water soluble inks, g. pH regulators in the dyeing of wool and polyamide fibers, h. foundry chemistry as a catalyst during curing, i. curing agents in many coating systems based on urethanes and amides, j. additives and flavoring agents in food, confectionary, and beverage products, k. synthetic fiber and clothing production, l. tetrahydrofuran production, m. gamma butyrolactone production, n. polybutylene terephthalate resin production, o. polyester raw materials for polyurethane elastomers and foams, p. coating resin raw material, and q. as an intermediate in the manufacture of other chemicals and pharmaceuticals. 2. At the request of any person, the Director of the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control may exempt any other product containing Gamma-Butyrolactone, Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol from being included as a Schedule I controlled substance if such product is labeled, marketed, manufactured and distributed for legitimate industrial use in a manner that reduces or eliminates the likelihood of abuse. 3. In making a determination regarding an industrial product, the Director, after notice and hearing, shall consider the following: a. the history and current pattern of abuse, b. the name and labeling of the product, c. the intended manner of distribution, advertising and promotion of the product, and d. other factors as may be relevant to and consistent with the public health and safety. 4. The hearing shall be held in accordance with the procedures of the Administrative Procedures Act. F. Any material, compound, mixture, or preparation, whether produced directly or indirectly from a substance of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, that contains any quantity of the following substances, or that contains any of their salts, isomers, and salts of isomers when the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: 1. JWH-004; 2. JWH-007; 3. JWH-009; 4. JWH-015; 5. JWH-016; 6. JWH-018; 7. JWH-019; 8. JWH-020; 9. JWH-030; 10. JWH-046; 11. JWH-047; 12. JWH-048; 13. JWH-049; 14. JWH-050; 15. JWH-070; 16. JWH-071; 17. JWH-072; 18. JWH-073; 19. JWH-076; 20. JWH-079; 21. JWH-080; 22. JWH-081; 23. JWH-082; 24. JWH-094; 25. JWH-096; 26. JWH-098; 27. JWH-116; 28. JWH-120; 29. JWH-122; 30. JWH-145; 31. JWH-146; 32. JWH-147; 33. JWH-148; 34. JWH-149; 35. JWH-150; 36. JWH-156; 37. JWH-167; 38. JWH-175; 39. JWH-180; 40. JWH-181; 41. JWH-182; 42. JWH-184; 43. JWH-185; 44. JWH-189; 45. JWH-192; 46. JWH-193; 47. JWH-194; 48. JWH-195; 49. JWH-196; 50. JWH-197; 51. JWH-198; 52. JWH-199; 53. JWH-200; 54. JWH-201; 55. JWH-202; 56. JWH-203; 57. JWH-204; 58. JWH-205; 59. JWH-206; 60. JWH-207; 61. JWH-208; 62. JWH-209; 63. JWH-210; 64. JWH-211; 65. JWH-212; 66. JWH-213; 67. JWH-234; 68. JWH-235; 69. JWH-236; 70. JWH-237; 71. JWH-239; 72. JWH-240; 73. JWH-241; 74. JWH-242; 75. JWH-243; 76. JWH-244; 77. JWH-245; 78. JWH-246; 79. JWH-248; 80. JWH-249; 81. JWH-250; 82. JWH-251; 83. JWH-252; 84. JWH-253; 85. JWH-262; 86. JWH-292; 87. JWH-293; 88. JWH-302; 89. JWH-303; 90. JWH-304; 91. JWH-305; 92. JWH-306; 93. JWH-307; 94. JWH-308; 95. JWH-311; 96. JWH-312; 97. JWH-313; 98. JWH-314; 99. JWH-315; 100. JWH-316; 101. JWH-346; 102. JWH-348; 103. JWH-363; 104. JWH-364; 105. JWH-365; 106. JWH-367; 107. JWH-368; 108. JWH-369; 109. JWH-370; 110. JWH-371; 111. JWH-373; 112. JWH-386; 113. JWH-387; 114. JWH-392; 115. JWH-394; 116. JWH-395; 117. JWH-397; 118. JWH-398; 119. JWH-399; 120. JWH-400; 121. JWH-412; 122. JWH-413; 123. JWH-414; 124. JWH-415; 125. CP-55, 940; 126. CP-47, 497; 127. HU-210; 128. HU-211; 129. WIN-55, 212-2; 130. AM-2201; 131. AM-2233; 132. JWH-018 adamantyl-carboxamide; 133. AKB48; 134. JWH-122 N-(4-pentenyl)analog; 135. MAM2201; 136. URB597; 137. URB602; 138. URB754; 139. UR144; 140. XLR11; 141. A-796,260; 142. STS-135; 143. AB-FUBINACA; 144. AB-PINACA; 145. PB-22; 146. AKB48 N-5-Fluorpentyl; 147. AM1248; 148. FUB-PB-22; 149. ADB-FUBINACA; 150. BB-22; 151. 5-Fluoro PB-22; or 152. 5-Fluoro AKB-48. G. In addition to those substances listed in subsection F of this section, unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a synthetic cannabinoid found to be in any of the following chemical groups: 1. Naphthoylindoles: any compound containing a 3-(1- naphthoyl)indole structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1- (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl- 2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the naphthyl ring to any extent. Naphthoylindoles include, but are not limited to: a. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH- 200), b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201), c. 1-pentyl-3-(1-naphthoyl)indole (JWH-018), d. 1-butyl-3-(1-naphthoyl)indole (JWH-073), e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081), f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015), g. 1-hexyl-3-(1-naphthoyl)indole (JWH-019), h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122), i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210), j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398), k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007), l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH-164), m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole (JWH-098), n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH-412), o. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1- naphthoyl)indole (AM-1220), p. 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole (MAM-2201), or q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM-2232); 2. Naphthylmethylindoles: any compound containing a 1H-indol-3- yl-(1-naphthyl)methane structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1- (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl- 2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the naphthyl ring to any extent. Naphthylmethylindoles include, but are not limited to, (1-pentylindol-3-yl)(1-naphthyl)methane (JWH-175); 3. Naphthoylpyrroles: any compound containing a 3-(1- naphthoyl)pyrrole structure with or without substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4- morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the pyrrole ring to any extent, and whether or not substituted on the naphthyl group to any extent. Naphthoylpyrroles include, but are not limited to: a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH-147), b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole (JWH-370), c. 1-pentyl-3-(1-naphthoyl)pyrrole (JWH-030), or d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole (JWH-147); 4. Naphthylideneindenes: any compound containing a 1-(1- naphthylmethylene)indene structure with or without substitution at the 3-position of the indene ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4- morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indene group to any extent, and whether or not substituted on the naphthyl group to any extent. Naphthylmethylindenes include, but are not limited to, (1-[(3-pentyl)-1H-inden-1- ylidene)methyl]naphthalene (JWH-176); 5. Phenylacetylindoles: any compound containing a 3- phenylacetylindole structure with or without substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1- (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl- 2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the phenyl ring to any extent. Phenylacetylindoles include, but are not limited to: a. 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250), b. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8), c. 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203), d. 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251), e. 1-pentyl-3-(4-methoxyphenylacetyl)indole (JWH-201), or f. 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH-302); 6. Cyclohexylphenols: any compound containing a 2-(3- hydroxycyclohexyl)phenol structure with or without substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4- morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, and whether or not further substituted on the cyclohexyl ring to any extent. Cyclohexylphenols include, but are not limited to: a. 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3- hydroxycyclohexyl]-phenol (CP-47,497), b. 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- phenol (cannabicyclohexanol; CP-47,497 C8 homologue), or c. 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3- hydroxypropyl)cyclohexyl]-phenol (CP 55, 940); 7. Benzoylindoles: any compound containing a 3-(benzoyl)indole structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl- 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the phenyl group to any extent. Benzoylindoles include, but are not limited to: a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4), b. 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4- methoxybenzoyl)indole (Pravadoline or WIN 48, 098), c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694), d. 1-pentyl-3-(2-iodobenzoyl)indole (AM-679), or e. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2- iodobenzoyl)indole (AM-2233); 8. Cyclopropoylindoles: Any compound containing a 3- (cyclopropoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl- 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the cyclopropoyl ring to any extent. Cyclopropoylindoles include, but are not limited to: a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole (UR-144), b. 1-(5-chloropentyl)-3-(2,2,3,3- tetramethylcyclopropoyl)indole (5Cl-UR-144), or c. 1-(5-fluoropentyl)-3-(2,2,3,3- tetramethylcyclopropoyl)indole (XLR11); 9. Indole Amides: Any compound containing a 1H-Indole-3- carboxamide structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl- 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxamide group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl- 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3- dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quninolinyl, or cycloalkyl rings to any extent. Indole Amides include, but are not limited to: a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (2NE1), b. N-(1-adamantyl)-1-(5-fluoropentyl-1H-indole-3- carboxamide (STS-135), c. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H- indole-3-carboxamide (ADBICA), d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5- fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA), e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide (NNE1), f. 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3- carboxamide (5F-NNE1), g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006), or h. N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F-SDB-006); 10. Indole Esters: Any compound containing a 1H-Indole-3- carboxylate structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl- 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxylate group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl- 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3- dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole Esters include, but are not limited to: a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB- 22), b. quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3- carboxylate (5F-PB-22), c. quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3- carboxylate (BB-22), d. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3- carboxylate (FDU-PB-22), or e. naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3- carboxylate (NM2201); 11. Adamantanoylindoles: Any compound containing an adamantanyl-(1H-indol-3-yl)methanone structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4- morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent. Adamantanoylindoles include, but are not limited to: a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H- indol-3-yl]methanone (AM1248), or b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB- 001); 12. Carbazole Ketone: Any compound containing (9H-carbazole-3- yl) methanone structure with or without substitution at the nitrogen atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1- (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl- 2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl- 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3- dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted at the carbazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Carbazole Ketones include, but are not limited to, naphthalen-1-yl(9-pentyl- 9H-carbazol-3-yl)methanone (EG-018); 13. Benzimidazole Ketone: Any compound containing (benzimidazole-2-yl) methanone structure with or without substitution at either nitrogen atom of the benzimidazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2- piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2- pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl- 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3- dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the benzimidazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Benzimidazole Ketones include, but are not limited to: a. naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2- l)methanone (JWH-018 benzimidazole analog), or b. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2- yl)(naphthalen-1-yl)methanone (FUBIMINA); and 14. Modified by Replacement: any compound defined in this subsection that is modified by replacement of a carbon with nitrogen in the indole, naphthyl, indene, benzimidazole, or carbazole ring. H. Any prescription drug approved by the federal Food and Drug Administration under the provisions of Section 505 of the Federal Food, Drug and Cosmetic Act, Title 21 of the United States Code, Section 355, that is designated, rescheduled or deleted as a controlled substance under federal law by the United States Drug Enforcement Administration shall be excluded from Schedule I and shall be prescribed, distributed, dispensed or used in accordance with federal law upon the issuance of a notice, final rule or interim final rule by the United States Drug Enforcement Administration designating, rescheduling or deleting as a controlled substance such a drug product under federal law, unless and until the State Board of Pharmacy takes action pursuant to Section 2-201 of this title. If the Board of Pharmacy does not take action pursuant to Section 2-201 of this title, the drug product shall be deemed to be designated, rescheduled or deleted as a controlled substance in accordance with federal law and in compliance with the Uniform Controlled Dangerous Substances Act. Added by Laws 1971, c. 119, § 2-204, operative Sept. 1, 1971. Amended by Laws 1976, c. 291, § 1, emerg. eff. June 17, 1976; Laws 1978, c. 194, § 3, emerg. eff. April 14, 1978; Laws 1984, c. 127, § 1, eff. Nov. 1, 1984; Laws 1987, c. 138, § 3, emerg. eff. June 19, 1987; Laws 1994, c. 140, § 1, eff. Sept. 1, 1994; Laws 1995, c. 54, § 2, eff. July 1, 1995; Laws 1998, c. 100, § 1, emerg. eff. April 13, 1998; Laws 2000, c. 16, § 1, emerg. eff. April 3, 2000; Laws 2001, c. 99, § 2, eff. July 1, 2001; Laws 2001, c. 373, § 2, eff. July 1, 2001; Laws 2005, c. 283, § 1, eff. Nov. 1, 2005; Laws 2008, c. 332, § 1, eff. Nov. 1, 2008; Laws 2010, c. 182, § 1, eff. Nov. 1, 2010; Laws 2011, c. 239, § 2, eff. Nov. 1, 2011; Laws 2012, c. 80, § 2, eff. Nov. 1, 2012; Laws 2013, c. 181, § 1, eff. Nov. 1, 2013; Laws 2014, c. 154, § 2, eff. Nov. 1, 2014; Laws 2015, c. 305, § 3; Laws 2017, c. 390, § 2, emerg. eff. June 6, 2017; Laws 2018, c. 134, § 1, eff. Nov. 1, 2018; Laws 2019, c. 207, § 1, eff. Nov. 1, 2019; Laws 2021, c. 222, § 2, eff. Nov. 1, 2021; Laws 2022, c. 70, § 1, eff. Nov. 1, 2022; Laws 2023, c. 120, § 1, eff. Nov. 1, 2023; Laws 2024, c. 308, § 3, emerg. eff. May 15, 2024.
999f43dfd4f3910b63 O.S. Sec. 2-101(48). a. "Synthetic controlled substance" means a substance: (1) the chemical structure of which is substantially similar to the chemical structure of a controlled dangerous substance in Schedule I or II, (2) which has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled dangerous substance in Schedule I or II, or (3) with respect to a particular person, which such person represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled dangerous substance in Schedule I or II. b. The designation of gamma-butyrolactone or any other chemical as a precursor, pursuant to Section 2-322 of this title, does not preclude a finding pursuant to subparagraph a of this paragraph that the chemical is a synthetic controlled substance. c. Synthetic controlled substance does not include: (1) a controlled dangerous substance, (2) any substance for which there is an approved new drug application, (3) with respect to a particular person any substance, if an exemption is in effect for investigational use, for that person under the provisions of Section 505 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C., Section 355, to the extent conduct with respect to such substance is pursuant to such exemption, or (4) any substance to the extent not intended for human consumption before such an exemption takes effect with respect to that substance. d. Prima facie evidence that a substance containing salvia divinorum has been enhanced, concentrated, or chemically or physically altered shall give rise to a rebuttable presumption that the substance is a synthetic controlled substance; 63 O.S. Sec. 2-401(C)(1). Except when authorized by the Food and Drug Administration of the United States Department of Health and Human Services, it shall be unlawful for any person to manufacture or distribute a controlled substance or synthetic controlled substance.
9783e31dff3f7d74"Industrial hemp" means the plant, Cannabis sativa L., and any part of the plant, including the seeds thereof, and all derivatives, extracts, cannabinoids, isomers, acids, salts and salts of isomers, whether growing or not, with a total delta-9 tetrahydrocannabinol concentration of not more than three-tenths of one percent (0.3%) on a dry weight basis. "Acceptable Hemp THC Level" means when a laboratory tests a sample, it shall report the total delta-9 tetrahydrocannabinol content concentration level on a dry-weight basis and the measurement of uncertainty. The acceptable hemp THC level, for the purpose of compliance with the requirements of the state hemp plan, is when the application of the measurement of uncertainty to the reported total delta-9 tetrahydrocannabinol content concentration level on a dry-weight basis produces a distribution or range that includes 0.3% or less. "Decarboxylated" means the completion of the chemical reaction that converts THC-acid (THCA) into total delta-9-THC, the intoxicating component of cannabis. The decarboxylated value is also calculated using a conversion formula that sums total delta-9-THC and eighty-seven and seven tenths (87.7) percent of THCA.
e3683eff33ae5b35Sec. 1-1432.2 Definitions. ... 3. "Kratom leaf" means the leaf of the kratom plant, Mitragyna speciosa ... The total alkaloid content of kratom leaf material ... shall not exceed three and one-half percent (3.5%) ... 4. "Kratom leaf extract" ... shall contain mitragynine as the most abundant alkaloid ... at a level that is equal to or exceeds twice that of any other alkaloid present ... 5. "Kratom product" means a food or dietary supplement that consists of or contains kratom leaf or kratom leaf extract that does not contain any synthesized kratom alkaloids ... or synthesized metabolites ... in which the level of 7-hydroxymitragynine, on a percent weight basis, is not greater than one percent (1%) of the amount of total kratom alkaloids ... 6. "Total kratom alkaloids" means the sum of mitragynine, speciociliatine, speciogynine, paynantheine, and 7-hydroxymitragynine; and 7. "Vendor" ... Sec. 1-1432.4 Prohibited products. A. A vendor shall not prepare, distribute, sell, or expose for sale: 1. A kratom product that does not meet the definition ...; 2. ... contaminated with a dangerous nonkratom substance ...; 3. A kratom product containing a level of 7-hydroxymitragynine in the alkaloid fraction that is greater than one percent (1%) of the alkaloid composition of the product; 4. A kratom product containing any synthesized alkaloid including synthesized mitragynine, synthesized 7-hydroxymitragynine or any other synthesized compounds of the kratom plant; 5. ... any controlled substance ... unless compounded by a licensed pharmacist ...; 6. ... residual solvent ... exceeding ICH Q3C ... B. [labeling incl. total kratom alkaloids, mitragynine, 7-OH amounts; under-18 prohibition]. C. A vendor may not distribute, sell, or expose for sale a kratom product to an individual under eighteen (18) years of age. D. ... test results on request.
Compound Laws, published by Compound Analytics, reports the record: statutes verbatim, official citations, enforcement facts and verification dates. Nothing here is legal advice and nothing here describes how to get around a law. A jurisdiction with no verified row is reported as not yet verified, never as legal. Found an error? Corrections policy.
About · Methodology · Glossary · Changes · Data & API · llms.txt · Sitemap